Vous avez cherché: patients (Espagnol - Finnois)

adjunctive treatment in patients at risk of methotrexate
adjunctive treatment in patients at risk of methotrexate toxicity

c02kx01 symptomatic treatment of patients with pulmonary arterial
c02kx01 symptomatic treatment of patients with

s01ad local treatment of cmv retinitis in patients with aids
s01ad local treatment of cmv retinitis in patients with aids

jo5ag0 3 combination therapy of hiv-1 infected patients
jo5ag03 combination therapy of hiv- 1 infected patients

b02bd04 treatment and prophylaxis of bleeding in patients with haemophilia b
b02bd04 treatment and prophylaxis of bleeding in patients with haemophilia b

b01ae prevention of venous thromboembolic events in patients undergoing major
b01ae

n06dx01 treatment of patients with moderately severe to severe alzheimer disease
n06dx01 treatment of patients with moderately severe

l03aa13 reduction in the duration of neutropenia in patients treated with cytotoxic chemotherapy
l03aa13 reduction in the duration of neutropenia in patients

long-term replacement therapy in patients with a confirmed diagnosis of fabry disease
patients with a confirmed diagnosis of fabry disease

b01ax indicated in purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein c
coumarin induced skin necrosis in patients with severe congenital protein c

b01ad10 treatment of adult patients with severe sepsis with multiple organ failure, when added to best standard care
b01ad10 treatment of adult patients with severe sepsis with multiple

concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment.
concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment.

points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi)
points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi)

the use of botulinum toxin type-b in the treatment of patients who have become unresponsive to botulinum toxin type-a -- initial experiences.
the use of botulinum toxin type- b in the treatment of patients who have become unresponsive to botulinum toxin type- a -- initial experiences.

h01ax (proposed) treatment of patients with acromegaly who had an inadequte response to surgery and/ or radiation therapy and who did not respond to treatment with somatostatin analogues
had an inadequte response to surgery and/ or radiation therapy and who did not respond to treatment with somatostatin analogues

el ensayo irma 2 (effects of irbesartan on microalbuminuria in hypertensive patients with type 2 diabetes mellitus) demostró que la dosis de 300 mg de irbesartan retrasa la progresión a proteinuria franca en pacientes con microalbuminuria.
irma 2 - tutkimus (effects of irbesartan on microalbuminuria in hypertensive patients with type 2 diabetes mellitus) osoittaa, että irbesartaani 300 mg hidastaa selvän proteinurian kehittymistä potilailla, joilla on mikroalbuminuria.

título del documento points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi) note for guidance on the clinical development of medicinal products for the treatment of hiv infection.
asiakirjan nimi points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi) note for guidance on the clinical development of medicinal products for the treatment of hiv infection.

(cpmp/ ewp/ 225/ 02) concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal failure.
(cpmp/ ewp/ 225/ 02)